Phuturdex › Drugs › Pegylated Liposomal Doxorubicin Hydrochloride
Drugs in development · updated 11 November 2026
Pegylated Liposomal Doxorubicin Hydrochloride: clinical trials and development status
Other names and codes: Liposomal Doxorubicin, DOXIL
As of 11 November 2026 Pegylated Liposomal Doxorubicin Hydrochloride is in 34 active clinical trials (recruiting or ongoing, phases I–III) for 34 diseases. The most advanced phase is III.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
Single use of pegylated liposomal doxorubicin has been reported to be safe and effective with varying treatment in patients with advanced hepatocellular carcinoma.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 34 diseases.
Sites in Europe
100 sites of the active trials in 15 European countries, 4 recruiting.
- France24
- Poland12
- Italy9
- Netherlands9
- United Kingdom7
- Germany6
- Austria5
- Greece5
- and 7 more
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Pegylated Liposomal Doxorubicin Hydrochloride
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.